Paperonium

← Back to the plain-language case

Trial report omits one of two registered primary outcomes and does not disclose the omission

Lancet Reg Health Am (2025) · doi:10.1016/j.lana.2025.101339 · PMC12795688 · NCT04316221

Summary

ClinicalTrials.gov NCT04316221 has listed two primary outcomes since its first version (2020-03-18): the Caregiver Reported Child Development Instruments (CREDI) and the Guide for Monitoring Child Development (GMCD), both with a 6-month time frame. The Outcome Measures section was never edited in any of the record's six versions. The published protocol lists both instruments as primary in its abstract and data-collection schedule (Figure 7), although the defining sentence of its Primary Outcomes subsection names only the CREDI. The paper, which presents itself as the trial's primary report, names a single primary outcome (the CREDI global development score). It does not mention the GMCD anywhere, and it does not say that a registered primary outcome was dropped or why. The reported CREDI result is null. No GMCD result is reported.

What was registered

The record history (ClinicalTrials.gov history API, versions 0 to 5; the web history tab numbers the same versions 1 to 6) shows these versions and changed modules:

Version (API) Date Modules changed Primary outcomes
0 2020-03-18 first version (submitted 2020-03-16, posted 2020-03-20) CREDI; GMCD
1 2021-01-29 Study Status (estimated start moved from 2020-06-01 to 2021-04-01) unchanged
2 2021-07-07 Study Status (start 2021-04-01 marked actual; recruiting), Contacts/Locations unchanged
3 2023-01-30 Study Status unchanged
4 2023-05-19 Study Status, Study Design (enrollment changed to actual), Contacts/Locations unchanged
5 2026-03-12 Study Status unchanged

The history summary reports "primaryOutcomesSame": true, "secondaryOutcomesSame": true and "outcomesUpdateCount": 0. The full records for versions 0, 1, 2, 4 and 5 were retrieved, and their primary-outcome entries are identical.

Guide for Monitoring Child Development (GMCD) · time frame: 6 months · "The GMCD has been used in low- and middle-income countries in children ages 0-24 months and focuses on seven areas: expressive language, receptive language, fine motor, gross motor, relating, play, and self-help." - Version 4 (2023-05-19), the last version before primary completion (2023-09-30) and before online publication (2025-12-20): the same two primary outcomes, with identical wording. - Version 5 (2026-03-12, after publication; current record): the same two primary outcomes. The record has no posted results (hasResults: false).

The registered secondary outcomes, all at 6 months, are "changes in infant hemoglobin", "weight-for-age", "length-for-age", "Head circumference" and "Infant diet quality" (WHO Infant and Young Child Feeding indicators).

Published protocol (J Acad Nutr Diet 2022;122:432–444, doi:10.1016/j.jand.2021.03.015, online 2021-05-04; also the paper's supplement mmc2.pdf). The protocol is internally inconsistent about the GMCD. Its abstract lists both instruments as primary:

"Primary outcomes for this study are changes in global development scores, assessed using the Guide for Monitoring Global Development and the Caregiver Reported Child Development Instruments."

The body's "Primary Outcomes" subsection, however, opens with a defining sentence that names only the CREDI:

"Primary outcomes for this study are differences in global development scores between study arms, assessed using the Caregiver Reported Early Child Development Instruments (CREDI) long form at baseline (ie, infants aged 6 to 9 months) and endline."

The same subsection then describes the GMCD: "The Guide for Monitoring Child Development is extensively used alongside the CREDI in low- and middle-income countries in children aged 0 to 24 months", and "Together the Guide for Monitoring Child Development and the CREDI ... provide complementary information about child development." Figure 7 of the protocol ("Data collection description and schedule") lists the GMCD under "Primary outcome" and schedules it at endline in both groups. Under "Protocol Amendments" the protocol says: "Any modification or addition will be communicated by updating the information on the www.clinicaltrials.gov website."

Because the protocol can be read either way, the main benchmark here is the registry, which the protocol itself names as the place where changes are recorded and which lists the CREDI and the GMCD as primary outcomes in all six versions.

What the paper reports

The paper states a single primary outcome:

"The primary outcome was the overall global development score from the Caregiver Reported Early Childhood Development Instruments (CREDI) long form, which has been validated in Guatemala and piloted previously by our team."

— Methods, "Sociodemographic variables and outcomes", paragraph 2

"We hypothesized that infants receiving a single whole egg per day and local standard nutrition care during the complementary feeding period would have improved global development (primary outcome) and growth, anemia status, and diet quality (secondary outcomes) relative to infants who received only local standard nutrition care."

— Introduction, final paragraph, which opens "We report primary findings from the Saqmolo’ Project"

"Mixed linear or logistic regression models were used to estimate between-group differences in primary (global development score) and secondary (growth, anemia status, and diet quality) outcomes."

— Abstract, Methods

Its statements about the registration, protocol and analysis plan are:

"This trial was preregistered with ClinicalTrials.gov (NCT04316221). A detailed trial protocol was published previously."

— Methods, first paragraph, which also says "The study followed the Consolidated Standards of Reporting Trials (CONSORT) reporting guideline."

"A detailed statistical analysis plan was made publicly available prior to data analysis."

— Methods, "Statistical analysis", first sentence (ref 51)

The archived PMC text, including the tables, figure legends and back matter, has no match for "GMCD" or "Guide for Monitoring". The supplementary tables (mmc1.docx) do not mention it either. The text contains no "amend" and no "deviat". The only departure from plan the paper describes concerns adherence monitoring: "More intensive weekly monitoring of self-reported egg consumption by telephone was planned but proved infeasible due to geographical limitations in cellular signal coverage."

The cited analysis plan (Harvard Dataverse doi:10.7910/DVN/1OSZOC, file "Saqmolo data analysis plan 1.19.2024.pdf", published 2024-01-23, after primary completion on 2023-09-30) says: "The primary endpoint for this study is differences between groups in child global development scores, as assessed using the Caregiver Reported Child Development Instruments (CREDI)." It does not mention the GMCD, and it does not say that the primary outcomes were changed from the registration or the protocol.

The discrepancy

Outcome Registered (version, date) In the paper Status
CREDI long form, global development score, 6 months Primary; v0 2020-03-18 to v5 2026-03-12, unchanged Sole primary outcome. Global raw scaled score at endline (6-month intervention), with domain scores as sensitivity analyses matched
Guide for Monitoring Child Development (GMCD), 6 months Primary; v0 2020-03-18 to v5 2026-03-12, unchanged. The published protocol (2021) lists it as primary in its abstract and data-collection schedule (Figure 7); its body's defining sentence names only the CREDI Not mentioned anywhere: not as a primary, secondary or exploratory outcome, and not in the limitations not reported
Infant hemoglobin, 6 months Secondary; v0 to v5 Secondary: altitude-adjusted hemoglobin and anemia matched
Weight-for-age, length-for-age, head circumference, 6 months Secondary; v0 to v5 Secondary: z scores plus underweight, stunting and low head circumference. Weight-for-length z, which the protocol lists, is also reported matched
Infant diet quality (WHO IYCF indicators), 6 months Secondary; v0 to v5 Secondary: minimum dietary diversity, minimum meal frequency, minimum adequate diet matched

The randomized sample (1200) matches the registered enrollment (1200, actual).

Figures

Timeline of NCT04316221 registry versions, study start, primary completion, protocol, analysis plan and publication

Figure 1. Timeline of the registration and publications. The upper lane shows the six ClinicalTrials.gov versions (blue; circles are versions before the registered study start, squares are versions after it). The darker band runs from the registered study start (2021-04-01) to primary completion (2023-09-30), and the lighter band covers the period after primary completion. No version changed the primary outcomes, so the figure has no outcome-change markers: every version lists the CREDI and the GMCD. The lower lane shows the registered start and primary-completion dates, the trial dates given in the paper (orange bar, 2021-05-28 to 2023-08-03), the published protocol (2021-05-04; CREDI and GMCD as primary in its abstract and Figure 7), the analysis plan deposited after primary completion (2024-01-23, CREDI only) and the paper (2025-12-20, CREDI only). The one version dated after primary completion, v5 (2026-03-12), also follows the paper's publication and still lists both primary outcomes.

Two-column diagram: registered primary outcomes CREDI and GMCD on the left, the paper's single CREDI primary outcome with its result on the right

Figure 2. Registered primary outcomes and the primary outcome reported. Left (blue): the two primary outcomes registered in v0 (2020-03-18), unchanged through v5 (2026-03-12). Right (orange): the primary outcome the paper reports, with its adjusted result (β −0.08 points, 95% CI −0.22 to 0.06, p = 0.26, Table 4). The CREDI connector is labelled "MATCHED" (same instrument, same 6-month time frame). The GMCD connector, labelled "NOT REPORTED", ends at a dashed box stating that the paper names the GMCD nowhere in the text, tables or supplementary tables and gives no reason. The note at the bottom summarises the protocol (both instruments primary in its abstract and Figure 7, only the CREDI in its body's defining sentence) and the analysis plan, which lists only the CREDI and states no change.

Why it matters

Explanations considered

  1. The paper is a secondary or partial report. This does not apply. The paper says "We report primary findings from the Saqmolo’ Project". It reports the registered secondary outcomes alongside the primary outcome and does not point to a separate report. A Europe PMC search for "Saqmolo" (2026-10-23) returns only this paper, the protocol (J Acad Nutr Diet 2022), a protocol abstract (Curr Dev Nutr 2021) and an egg-composition study (Food Sci Nutr 2023). None of them reports GMCD results.
  2. The change is disclosed. It is not. The paper's only statements about the registration and plans are that the trial "was preregistered", that a protocol "was published previously" and that an analysis plan "was made publicly available prior to data analysis". None of them mentions the GMCD or a change in primary outcomes. The limitations section does not address it either.
  3. A documented protocol amendment explains it. None was found. The registry's Outcome Measures module was never edited in six versions (2020-03-18 to 2026-03-12), even though the protocol commits to communicating outcome changes "by updating the information on the www.clinicaltrials.gov website". The analysis plan (version 1.19.2024) lists only the CREDI, so a narrowing appears there. But the plan does not say that it departs from the registered or protocol primary outcomes, gives no reason, and is dated after primary completion. Citing the plan therefore does not, by itself, disclose the change to the reader. Whether the GMCD was administered at all is not stated in any of these documents.
  4. The two names refer to the same outcome. They do not. The CREDI and the GMCD are separate instruments. The registry lists them as two primary outcomes with different descriptions (caregiver-report CREDI with five domains; GMCD with seven areas), and the protocol cites them separately and schedules them separately (Figure 7). The protocol abstract's "Guide for Monitoring Global Development" is a naming variant of the same GMCD: the protocol's Outcomes section and Figure 7 call it "Guide for Monitoring Child Development". The paper's single primary outcome is explicitly the CREDI score.
  5. Time-point or metric differences. These are not at issue. The CREDI is analysed at the 6-month endline, consistent with the registered time frame. The difference concerns which outcomes are reported, not when they were measured.
  6. A later correction resolves it. None was found (see Status).
  7. The protocol already made the CREDI the sole primary outcome. Partly. The defining sentence of the protocol's Primary Outcomes subsection names only the CREDI, while its abstract and Figure 7 list the GMCD as primary as well, so the protocol is ambiguous. The registry, which the protocol designates for recording any modification, lists both as primary in every version, and the paper cites the registration. The protocol's ambiguity therefore does not disclose to the paper's readers that a registered primary outcome is not reported.

The documents do not show why the GMCD is absent, and this write-up makes no inference about the reason. A change of outcomes can have legitimate reasons, such as feasibility, instrument availability or field constraints. The issue documented here is that the omission is not disclosed.

Status

As of 2026-10-23:

Suggested correction

A correction to the article that:

  1. states that ClinicalTrials.gov NCT04316221 (and the abstract and Figure 7 of the published protocol) listed two primary outcomes at 6 months, the CREDI and the Guide for Monitoring Child Development (GMCD), and that the article reports only the CREDI;
  2. says whether GMCD data were collected and, if not, when and why the decision was made;
  3. if the GMCD was collected, reports the between-group result with the same models used for the CREDI (or a reason it cannot be reported), and says when the decision to make the CREDI the sole primary outcome was taken relative to the analysis plan (version 1.19.2024) and to the start of outcome analysis, as CONSORT item 6b asks for any change to trial outcomes;
  4. qualifies the abstract's conclusion that the intervention "did not benefit development" as resting on the caregiver-reported CREDI only.

Separately, the ClinicalTrials.gov record could be updated to reflect the outcomes actually analysed, with the change and its reason noted, as the protocol's amendment section anticipates.